Compare ONMD & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ONMD | PASG |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | 22 | 27 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.7M | 28.3M |
| IPO Year | N/A | 2020 |
| Metric | ONMD | PASG |
|---|---|---|
| Price | $0.71 | $8.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $23.50 |
| AVG Volume (30 Days) | ★ 10.3M | 28.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.30 | $0.28 |
| 52 Week High | $4.22 | $20.00 |
| Indicator | ONMD | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 43.38 |
| Support Level | $0.60 | $8.10 |
| Resistance Level | $0.91 | $8.85 |
| Average True Range (ATR) | 0.11 | 0.73 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 14.91 | 43.43 |
OneMedNet Corp is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. It is a provider of clinical imaging innovation and curator of regulatory-grade Imaging Real World Data(iRWDTM). Its solutions connect healthcare providers and patients, satisfying a crucial need within the life sciences field, offering direct access to clinical images and the associated contextual patient record. OneMedNet's technology has provens the commercial and regulatory viability of imaging Real World Data (as defined below), an emerging market, and provides regulatory-grade, image-centric iRWDTM that exactly matches OneMedNet's life science partners' case selection protocols, paving the way for Real World Evidence.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.